As of November 10, 2026, Mind Medicine (MindMed) Inc. is a publicly traded company (Nasdaq: DFTX); its largest reported holder is Fidelity (FMR), with 6.5% on Schedule 13G of November 5, 2026, then Driehaus Capital Management LLC (5.36%). The largest insider holding is Robert Barrow, the chief executive and a director, with 2,213,090 shares (1.6% of shares outstanding), per Form 4 of September 29, 2026 (Schedule 13G, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Mind Medicine (MindMed) Inc.? See the free Snapshot first.
Free to see. No signup.
Is Mind Medicine (MindMed) Inc. a real, registered company?
- Definium Therapeutics, Inc. files with the SEC under CIK 1813814 (its SEC filings).
- Its shares are listed under the ticker DFTX on Nasdaq (SEC company record).
- Incorporated in A1; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Mind Medicine (MindMed) Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Mind Medicine (MindMed) Inc.'s owners and officers?
Mind Medicine (MindMed) Inc.: business address in New York, New York; industry Medicinal Chemicals & Botanical Products (Schedule 13G, 2026-11-05).
Officers and directors, each with the role and the filing that names them:
- : Director, Executive Officer (Form D, 2025-05-05)
- : Executive Officer (Form D, 2025-05-05)
- : Executive Officer (Form D, 2025-05-05)
- : Executive Officer (Form D, 2025-05-05)
- : Executive Officer (Form D, 2025-05-05)
- : Director (Form D, 2025-05-05)
- : Director (Form D, 2025-05-05)
- : Director (Form D, 2025-05-05)
- : Director (Form D, 2025-05-05)
- : Director (Form D, 2025-05-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-05 | Fmr LLC | 6.5% |
| Schedule 13G/A, 2026-08-14 | Driehaus Capital Management LLC | 5.36% |
| Schedule 13G/A, 2026-08-14 | Commodore Capital LP | 1.8% |
| Schedule 13G/A, 2026-05-15 | Deep Track Capital, LP | 3.01% |
| Schedule 13G, 2026-02-17 | Avoro Capital Advisors LLC | 5.08% |
| Schedule 13G, 2026-02-17 | Driehaus Capital Management LLC | 6.64% |
| Schedule 13G/A, 2026-02-17 | Commodore Capital LP | 7.2% |
| Schedule 13G/A, 2026-02-13 | Deep Track Capital, LP | 5.54% |
| Schedule 13G/A, 2025-11-14 | Deep Track Capital, LP | 6.87% |
Questions about who owns Mind Medicine (MindMed) Inc.
Who owns Mind Medicine (MindMed) Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Mind Medicine (MindMed) Inc.: Fmr LLC (6.5%, Schedule 13G, filed 2026-11-05), Driehaus Capital Management LLC (5.36%, Schedule 13G/A, filed 2026-08-14) and Avoro Capital Advisors LLC (5.08%, Schedule 13G, filed 2026-02-17).
Who are the largest shareholders of Mind Medicine (MindMed) Inc.?
By the share each holder's latest filing reports, the largest holders of Mind Medicine (MindMed) Inc. on this page are Fmr LLC (6.5%), Driehaus Capital Management LLC (5.36%) and Avoro Capital Advisors LLC (5.08%).
When did Fmr LLC buy into Mind Medicine (MindMed) Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-11-05, reporting 6.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Mind Medicine (MindMed) Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mind Medicine (MindMed) Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mind Medicine (MindMed) Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Mind Medicine (MindMed) Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 2,213,090 shares (1.6% of shares outstanding) (Form 4, 2026-09-29).
- , the chief medical officer and a director: 792,846 shares (0.58% of shares outstanding) (Form 4, 2026-09-29).
- , the chief legal officer: 494,228 shares (0.36% of shares outstanding) (Form 4, 2026-09-29).
- , the chief financial officer: 394,528 shares (0.29% of shares outstanding) (Form 4, 2026-09-29).
- , the chief commercial officer: 359,036 shares (0.26% of shares outstanding) (Form 4, 2026-09-29).
Shares outstanding: 136,899,935 as of 2026-11-02, from the company's latest SEC cover page.
How much has Mind Medicine (MindMed) Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-05-05 | $7M | $7M |
| Form D, 2024-03-18 | $75M | $75M |
Keep reading
More on Mind Medicine (MindMed) Inc. and the records around it.
Mind Medicine (MindMed) Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing May 2025
Companies that share a holder
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Cue Biopharma, Inc. (Aug 2026), Frequency Electronics, Inc. (Aug 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/definium-therapeutics